Benperidol
Trade name: glianimon
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
1
Earliest trial started Nov 1, 2014 (NCT02307396)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Benperidol is a butyrophenone derivative and a specific dopamine antagonist, selective for the D2 receptor. It also binds to serotonin receptors but to a lesser extent. In high doses it has anti histaminergic and alpha-adrenergic properties but its anticholinergic effects are small.
Benperidol has high affinity and selectivity for binding to central D2-like specific binding sites.
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1- Mol. weight
- 381.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL297302 ↗
Also known as
- anquil
- anquil
- benperidol
- benperidol
- benperidol
- benperidol
- benperidol
- benperidol
- benperidol
- benperidol
- benquil
- benquil
- benzoperidol
- benzperidol
- frenactil
- frenactyl
- glianimon
- mcn-jr-4584
- mcn-jr-4584
- r-4584
- r-4584
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02374567 | Phase 3 | Jan 1, 2015 | Gottfried Wilhelm Leibniz Universität Hannover |
| NCT02307396 | Phase 4 | Nov 1, 2014 | Technical University of Munich |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Technical University of Munich | Academic/Hospital | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1